Analyst Reco. Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
72.13 ^USD	-1.35%		+0.18%	+0.71%

Apr. 23	Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating	MT
Apr. 22	Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating	Apr. 23	MT
Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	Apr. 22	MT
Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating	Apr. 22	MT
Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating	Apr. 17	MT
BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating	Apr. 17	MT
Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating	Apr. 17	MT
TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating	Apr. 17	MT
Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept	Apr. 17	MT
Needham Adjusts Intra-Cellular Therapies Price Target to $82 From $72, Maintains Buy Rating	Feb. 23	MT
Mizuho Increases PT on Intra-Cellular Therapies to $82 From $76 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	Feb. 15	MT
Goldman Sachs Raises Intra-Cellular Therapies' Price Target to $64 From $58, Keeps Neutral Rating	Jan. 18	MT
Baird Initiates Intra-Cellular Therapies With Outperform Rating, Price Target is $83	Jan. 03	MT
RBC Boosts Price Target on Intra-Cellular Therapies to $86 From $76, Keeps Outperform Rating	Jan. 03	MT
TD Cowen Starts Coverage on Intra-Cellular Therapies with Outperform Rating, $75 Price Target	Dec. 11	MT
RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating	Nov. 03	MT
Needham Adjusts Price Target on Intra-Cellular Therapies to $72 From $73, Maintains Buy Rating	23-08-04	MT
RBC Lifts Price Target on Intra-Cellular Therapies to $79 From $78, Keeps Outperform Rating	23-08-04	MT
RBC Raises Intra-Cellular Therapies' Price Target to $78 From $76, Keeps Outperform Rating	23-07-07	MT
Needham Adjusts Intra-Cellular Therapies' Price Target to $73 From $70, Keeps Buy Rating	23-07-06	MT
UBS Adjusts Intra-Cellular Therapies Price Target to $80 From $74, Maintains Buy Rating	23-06-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Analyst Reco.

Filters